Nath Bio-Genes (India) Q3 FY26 investor presentation: Revenue & Margins

The presentation does not explicitly detail any capex, capacity expansion, new plant, or project with specific amounts, status, or timelines. It focuses mainly on financial performance, business highlights, product growth, and strategic focus areas such as diversification, innovation, and operational efficiency. There are references to: - Strengthening international presence via the Uzbekistan joint venture (status: operating successfully). - Expansion of product basket and supply chain network (20,000 distributors, 17 branch offices, 10 processing plants, warehouses across 23 states), but no new specific projects or capex values are mentioned. - Strategic focus areas include accelerating growth in high-margin products and R&D but without quantitative details or timelines. No direct capital expenditure figures, new capacity additions, or project timelines are provided in the available excerpts.

The provided investor presentation does not explicitly mention or report any details regarding: - Order book - Order inflow - Pending orders No specific figures or commentary related to order backlog or new order acquisition are included in the slides or pages shared. The presentation primarily focuses on financial performance, including income statements, balance sheets, margins, profitability, and contact information, without reference to operational metrics like order book status.